Stockscreener 앱 받기
12.30
5.76%
0.67
시간 외 거래:
12.18
-0.12
-0.98%
전일 마감가:
$11.63
열려 있는:
$12.18
하루 거래량:
3.58M
Relative Volume:
1.11
시가총액:
$2.32B
수익:
$42.73M
순이익/손실:
$-204.38M
주가수익비율:
-10.15
EPS:
-1.2124
순현금흐름:
$-189.73M
1주 성능:
+3.36%
1개월 성능:
-15.41%
6개월 성능:
+84.68%
1년 성능:
+30.30%
1일 변동 폭
$12.01
$12.67
1주일 범위
$11.13
$12.67
52주 변동 폭
$5.28
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
명칭
Wave Life Sciences Ltd
전화
617-949-2900
주소
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
12.30 | 2.19B | 42.73M | -204.38M | -189.73M | -1.2124 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-05 | 개시 | BofA Securities | Buy |
| 2025-12-12 | 재확인 | Wedbush | Outperform |
| 2025-12-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-04 | 개시 | Canaccord Genuity | Buy |
| 2025-07-28 | 개시 | Oppenheimer | Outperform |
| 2025-07-16 | 개시 | Citigroup | Buy |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Wedbush | Outperform |
| 2025-02-25 | 개시 | Jefferies | Buy |
| 2024-10-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | 재개 | JP Morgan | Overweight |
| 2024-09-19 | 개시 | B. Riley Securities | Buy |
| 2024-09-09 | 개시 | JP Morgan | Overweight |
| 2024-05-15 | 개시 | Wells Fargo | Overweight |
| 2023-12-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Raymond James | Outperform |
| 2023-05-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-07-15 | 개시 | Cowen | Market Perform |
| 2019-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2018-08-07 | 개시 | Stifel | Buy |
| 2018-07-23 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 재확인 | Mizuho | Buy |
| 2017-02-15 | 개시 | H.C. Wainwright | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-07 | 개시 | Jefferies | Buy |
| 2015-12-07 | 개시 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Wave Life Sciences Ltd 주식(WVE)의 최신 뉴스
Jefferies reiterates Buy on Wave Life Sciences stock ahead of May data - Investing.com
Guidance Update: Can Wave Life Sciences Ltd beat the S P 5002026 AllTime Highs & Expert Verified Movement Alerts - baoquankhu1.vn
WVE: Mizuho Maintains Outperform, Raises Price Target to $27 | W - GuruFocus
WAVE Life Sciences (NASDAQ:WVE) Price Target Raised to $27.00 at Mizuho - MarketBeat
Here’s What Boosted Wave Life Sciences Ltd. (WVE) in Q4 - Insider Monkey
Mizuho raises Wave Life Sciences stock price target on obesity drug progress - Investing.com UK
Avoiding Lag: Real-Time Signals in (WVE) Movement - Stock Traders Daily
Traders Purchase Large Volume of WAVE Life Sciences Put Options (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Hits Day Low of $13.59 Amid Price Pressure - Markets Mojo
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2025 earnings call transcript - MSN
Quarterly Trades: Does Wave Life Sciences Ltd stock have upside surprise potential2026 Macro Moves & Weekly Return Optimization Plans - baoquankhu1.vn
WVE Stock Price, Quote & Chart | WAVE LIFE SCIENCES LTD (NASDAQ:WVE) - ChartMill
Wave Life Sciences reports positive early data from obesity drug trial - MSN
WVE Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
WAVE Life Sciences teams prepare to share development insights at OPTBoston - Traders Union
BofA highlights WVE-007 as primary driver for Wave Life Sciences Ltd. (WVE)’s growth, projecting peak sales above $11B - MSN
Cinctive Capital Management LP Lowers Holdings in WAVE Life Sciences Ltd. $WVE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF) - The Globe and Mail
Assessing Wave Life Sciences (WVE) Valuation After WVE-007 Obesity Data And Cash Runway Update - simplywall.st
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Discipline and Rules-Based Execution in WVE Response - Stock Traders Daily
Dynamic SXSW panel reshapes obesity treatment narrative, WAVE Life Sciences asserts - Traders Union
Canaccord Genuity Boosts Price Target for WAVE Life Sciences (WV - GuruFocus
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) - Benzinga
WAVE Life Sciences (NASDAQ:WVE) Given New $52.00 Price Target at Canaccord Genuity Group - MarketBeat
Wave Life Sciences (WVE) soars to 6-year high on obesity drug clinical trial - MSN
Wave Life Sciences to present WVE-006 trial data at ATS - Investing.com Nigeria
Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval PushWhat's Changed - simplywall.st
Wave Life Sciences Bets on Data Over Near-Term Revenue - TipRanks
WVE: Wedbush Raises Price Target for WAVE Life Sciences, Reaffir - GuruFocus
Wave Life Sciences (WVE) Valuation Check After New RNA Editing And Obesity Trial Updates - simplywall.st
Wedbush Forecasts Strong Price Appreciation for WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
Wave Life Sciences (WVE) Anticipates Positive Developments with WVE-007 Data - GuruFocus
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Sahm
Wave Life Sciences to present WVE-006 trial data at ATS By Investing.com - Investing.com Canada
Wave Life Sciences announces acceptance of late-breaking oral presentation on Wve-006 for alpha-1 antitrypsin deficiency at the American Thoracic Society international conference - marketscreener.com
Wave Life Sciences Announces Acceptance of Late-Breaking - GlobeNewswire
Q1 EPS Forecast for WAVE Life Sciences Raised by Analyst - MarketBeat
FY2029 Earnings Forecast for WVE Issued By HC Wainwright - MarketBeat
Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside - simplywall.st
WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan
Wave Life Sciences Ltd. (WVE) Stock Analysis: Biotechnology Innovator with 140% Upside Potential - DirectorsTalk Interviews
How Strong Q4 Revenue Amid Deeper Losses At Wave Life Sciences (WVE) Has Changed Its Investment Story - Yahoo Finance
Wave Life Sciences (WVE) Earnings Call Transcript - AOL.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Reiterates "Buy" Rating for WAVE Life Sciences (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Teases Near-Term Obesity and RNA Editing Data as INLIGHT Readouts Near - Yahoo Finance
Artisan Partners Limited Partnership Trims Stake in WAVE Life Sciences Ltd. $WVE - MarketBeat
How Mixed Q4 Results, Obesity Data and Cash Runway News At Wave Life Sciences (WVE) Has Changed Its Investment Story - simplywall.st
Wave Life Sciences Ltd. (WVE): A Bull Case Theory - Finviz
Wave Life Sciences Ltd (WVE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):